Irinotecan Inactivation Is Modulated by Epigenetic Silencing of UGT1A1 in Colon Cancer
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Purpose: Irinotecan is used in the first-line treatment of metastatic colorectal cancer. The UGT1A1-metabolizing enzyme, expressed in liver and colon, is primarily involved in the inactivation of its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Herein, we explored the role of DNA methylation in the silencing of UGT1A1 gene expression in colon cancer and its influence on cellular SN-38 detoxification. Experimental Design and Results: UGT1A1 mRNA was repressed in most primary tumors (41 of 50; 82%) and in three colon cancer cell lines (HCT-116, HCT-15, and COLO-320DM). Bisulfite sequencing of the UGT1A1 gene revealed the aberrant methylation of specific CpG islands in UGT1A1-negative cells. Conversely, hypomethylation was observed in HT-29, HT-115, and LOVO cells that overexpress UGT1A1. Direct methylation of the UGT1A1 promoter resulted in the complete repression of transcriptional activity. Treatment with demethylating and histone deacetylase inhibitor agents had the capacity to reverse aberrant hypermethylation and to restore UGT1A1 expression in hypermethylated UGT1A1-negative cells but not in hypomethylated cells. Loss of UGT1A1 methylation was further associated with an increase in UGT1A1 protein content and with an enhanced inactivation of SN-38 by 300% in HCT-116 cells. Conclusions: We conclude that DNA methylation represses UGT1A1 expression in colon cancer and that this process may contribute to the level of tumoral inactivation of the anticancer agent SN-38 and potentially influence clinical response.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, the transcription level of UGT1A1 is negatively regulated by DNA methylation [111].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [111]
Citations
Cites
Jaenisch, R., & Bird, A. (2003) · Nature Genetics · doi:10.1038/ng1089 · Cited by 6,325
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
Evans, W. E., & Relling, M. V. (1999) · Science · doi:10.1126/science.286.5439.487 · Cited by 2,475
Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,224
Human UDP-Glucuronosyltransferases: Metabolism, Expression, and Disease
Tukey, R. H., & Strassburg, C. P. (2000) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.581 · Cited by 1,523
Ando, Y., Saka, H., Ando, M., Sawa, T., Muro, K., Ueoka, H., Yokoyama, A., Saitoh, S., Shimokata, K., & Hasegawa, Y. (2000) · PubMed · Cited by 783
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
Iyer, L., Das, S., Janisch, L., Wen, M., Ramírez, J., Karrison, T., Fleming, G. F., Vokes, E. E., Schilsky, R. L., & Ratain, M. J. (2002) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500072 · Cited by 720
Emerging concepts in colorectal neoplasia
Jass, J. R., Whitehall, V. L. J., Young, J., & Leggett, B. A. (2002) · Gastroenterology · doi:10.1053/gast.2002.35392 · Cited by 495
Plumb, J. A., Strathdee, G. R., Sludden, J., Kaye, S. B., & Brown, R. E. (2000) · PubMed · doi:10.25405/ncl.34284429 · Cited by 486
Yang, X., Phillips, D. L., Ferguson, A. T., Nelson, W. G., Herman, J. G., & Davidson, N. E. (2001) · PubMed · Cited by 430
Sugatani, J., Kojima, H., Ueda, A., Kakizaki, S., Yoshinari, K., Gong, Q.-H., Owens, I. S., Negishi, M., & Sueyoshi, T. (2001) · Hepatology · doi:10.1053/jhep.2001.24172 · Cited by 381
Research works printed but not linked: 2
- American Cancer Society. Colorectal cancer facts & figures. Special edition 2005. Atlanta: American Cancer Society; 2005.
- Strassburg CP, Manns MP, Tukey RH. Expression of the UDP-glucuronosyltransferase 1A locus in human colon. Identification and characterization of the novel extrahepatic UGT1A8. J Biol Chem 1998;273:8719–26. · DOI · Paper page
Cited by
Drug resistance in cancer: An overview
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014) · Cancers · doi:10.3390/cancers6031769 · Cited by 2,463
The UDP-Glycosyltransferase (UGT) Superfamily: New Members, New Functions, and Novel Paradigms
Meech, R., Hu, D. G., McKinnon, R. A., Mubarokah, S. N., Haines, A. Z., Nair, P. C., Rowland, A., & Mackenzie, P. I. (2019) · Physiological Reviews · doi:10.1152/physrev.00058.2017 · Cited by 368
Drug resistance in cancer: mechanisms and tackling strategies
Haider, T., Pandey, V., Banjare, N., Gupta, P. N., & Soni, V. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00138-7 · Cited by 282
Epigenetic regulation of Keap1-Nrf2 signaling
Guo, Y., Yu, S., Zhang, C., & Kong, A.-N. T. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.013 · Cited by 258
A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development
Oda, S., Fukami, T., Yokoi, T., & Nakajima, M. (2015) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2014.12.001 · Cited by 232
Metadata
- Authors
- Gagnon, J.-F., Bernard, O., Villeneuve, L., Têtu, B., & Guillemette, C.
- Affiliations
- Hôtel-Dieu de Québec (CA)
- 1Canada Research Chair in Pharmacogenomics and
- ORCID
- Guillemette, Chantal
- Venue
- Clinical Cancer Research
- Published
- 2006-03-15
- Volume
- 12
- Issue
- 6
- Pages
- 1850-1858
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2055695109
- Cited by
- 93
- References
- 50
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 2 · 2023: 2 · 2022: 10 · 2021: 5 · 2020: 5 · 2019: 4 · 2018: 5 · 2017: 3 · 2016: 6 · 2015: 4 · 2014: 6 · 2013: 10 · 2012: 7
- FWCI
- 1.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- irinotecan, UGT1A1, DNA methylation, epigenetic silencing, colon cancer, colorectal cancer, promoter hypermethylation, hypomethylating agents, histone deacetylase inhibitors, drug resistance
- MeSH terms
- Irinotecan, Decitabine, UGT1A1 Enzyme, Azacitidine, Camptothecin, Humans, Hydroxamic Acids, Glucuronosyltransferase, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, CpG Islands, HT29 Cells, DNA Methylation, Glucuronides, HCT116 Cells, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Irinotecan Inactivation Is Modulated by Epigenetic Silencing of UGT1A1 in Colon Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-05-2130
- The paper
- Gagnon, J.-F., Bernard, O., Villeneuve, L., Têtu, B., & Guillemette, C. (2006). Irinotecan Inactivation Is Modulated by Epigenetic Silencing of UGT1A1 in Colon Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-05-2130
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.